Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Retrieved on:
Monday, December 19, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DCR, Roberto Lamarca, EAP, BeiGene, Webcast, Epitope, DOR, COVID-19, BTC, Systematic review, Safety, Conjugation, Corr, Research, Engineering, Patient, CLIN, HER2, Inc., IHC, Authorization, Endoscopic mucosal resection, Cohort, Progression-free survival, Tislelizumab, Drug development, Response evaluation criteria in solid tumors, Diagnosis, GEA, Gallbladder cancer, Cholangiocarcinoma, ISH, ICR, Adjuvant, Security (finance), RECIST, Drug Quality and Security Act, Clinical trial, Jazz, In situ hybridization, PFS, Zymeworks, Legislation, Pharmaceutical industry, Medical imaging
The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
Key Points:
- The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
- Full results from the pivotal trial are expected to be presented at a medical meeting in 2023.
- Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2.
- Zymeworks continues to enroll subjects in the Phase 3 randomized clinical trial, HERIZON-GEA-01, evaluating zanidatamab in combination with chemotherapy plus or minus tislelizumab for HER2-expressing GEA.